Tumor Tissue
Transform your cancer research with the innovative inCHIPit™ and comPLATE™ combination. Create a fully tumor-derived model that mimics the original tumor and get one step closer to unlocking the underlying mechanisms of cancer.

Get direct access to your tumor tissue from the top and observe the progress of your research with ease through the optically transparent window on the bottom. In addition, with the ability to line the microfluidic channel with endothelial cells, you can create a perfusable 3D blood vessel and stimulate the growth of your tumor model.
This not only gives you a more accurate representation of the original tumor, but it also allows you to test the impact of chemotherapies and other substances on the growth and spread of the cancer.
The inCHIPit™ and comPLATE™ are the perfect tools for a more in-depth understanding of the complexities of cancer!
Cancer treatment faces major challenges in defining the optimal therapy for each individual patient. Although there have been several strategies employed for this, to date, none have been able to reliably predict individual response. Therefore, ex vivo assays that can predict this response would strongly aid selection of the most effective treatment for each patient tumor(s).
In this article, we show how tumor tissue was cultured in the Bi/ond organ-on-chip system, consisting of the inCHIPit™ 3C with the comPLATE™, here referred to as cancer-on-chip (CoC) system. Breast PDX tumor and prostate PDX tumor PC82 slices were either cultured in 6-well standard plates (referred to as ex vivo culture) or in the Bi/ond CoC platform in duplicates.
Scientist removed tissue slices from the chip at either day 7 or day 14 and fixed them in formalin and embedded them in paraffin for microscopic analysis. First, the condition of the cells in the 6-well ex vivo culture was compared with that of the cells in the CoC platform after 7 and 14 days of culturing.
The obtained proliferation and cell death data indicate that the CoC platform provides better culture conditions for extended culture times (beyond 7 days) of tumor tissue slices than the ex vivo system. There are already subtle differences between both culture methods even after 7 days, as shown in the figure on the right.
Next, researchers treated breast tumor slices for 3 days with Cisplatin. Tissue cultured in the CoC platform showed a decrease in replicating (s-phase) cells and significant increase in apoptotic cells as compared to ex vivo culturing. In the figure on the right you can see EdU-positive (replicating) cells and TUNEL-positive (apoptotic) cells at day 0 (D0), day 3 (D3) and at day 3 after treatment with Cisplatin (D3Cis). This response to cisplatin treatment correlated well with the known tumor response in vivo as well as in ex vivo cultures.
A similar response in replicating and apoptotic cells was seen after 7 days of apalutamide exposure of prostate tumor slices. Again, this was comparable to the effect of antiandrogen treatment in in vivo and ex vivo cultures.
Bi/ond protects your privacy: when you request a quote, documentation or price options your personal data will be transferred to the Bi/ond team who will be able to contact you directly. See our Privacy Policy for details on the method used to process your data, the purpose and your rights concerning this data. By continuing to use our website you agree to our General Terms of Use.
Click to download the items.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
More information about our Cookie Policy